PTPN22 has the most significant multitarget intervention potential, while FAM175B and PROM2 are linked to tumor and inflammation pathways, and the specific interactions of LRRTM4 may guide precision treatment strategies. This evidence concerns the gene PTPN22 and neoplasm.